Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic Chemotherapy
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Aprepitant and olanzapine have been recommended for emesis prevention from highly emetogenic
chemotherapy. We hypothesized that olanzapine may lead to less nausea compared to aprepitant
based on previous study. However, data of combination of olanzapine and ondansetron is
scarce.